InvestorsHub Logo
Followers 7
Posts 571
Boards Moderated 0
Alias Born 08/25/2012

Re: sorkin post# 1786

Tuesday, 08/06/2019 2:58:13 PM

Tuesday, August 06, 2019 2:58:13 PM

Post# of 1954
7/15/2019 22,751,462 shares short
Continues to drop. What happens to these shorts if Phase II trials are announced with a 2.5mg arm? An effective drug at 20mg with a go forward side effect profile. A very broad range of dosages allows for a lot of interesting things to be tried.
Madrigal is ahead in trials with a best class of NASH drugs in a phase 3 trail, but may be having a problem looking over it's shoulder with Vikings best in class.

GLTA, the catalysts to move this stock are getting near
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent VKTX News